Publication: Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
Issued Date
2014-12-01
Resource Type
ISSN
21911991
Other identifier(s)
2-s2.0-84971330865
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Health Economics Review. Vol.4, No.1 (2014), 1-7
Suggested Citation
Sukit Yamwong, Unchalee Permsuwan, Sirana Tinmanee, Piyamitr Sritara Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. Health Economics Review. Vol.4, No.1 (2014), 1-7. doi:10.1186/s13561-014-0017-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34156
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
Other Contributor(s)
Abstract
© 2014, Yamwong et al.; licensee Springer. Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database. Methods: A one-year decision tree and a long-term Markov model were constructed to estimate lifetime costs and quality-adjusted life years (QALYs). For the first year, data from PLATO (NCT00391872) were used to estimate the rate of cardiovascular events, resource use, and QALYs. For year 2 onwards, clinical effectiveness was estimated conditional on individual health states that occurred during the first year. Results: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) with ticagrelor was 292,504 ($9,476) and 60,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel. Conclusions: This health economic analysis provides cost effectiveness data for ticagrelor compared with both generic and branded clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically valuable treatment for ACS compared with branded clopidogrel within the Thai context.